The prognostic role of different renal function phenotypes in patients with acute heart failure.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
01 Feb 2019
Historique:
received: 16 05 2018
revised: 25 10 2018
accepted: 21 11 2018
pubmed: 7 12 2018
medline: 28 8 2019
entrez: 4 12 2018
Statut: ppublish

Résumé

Worsening renal function (WRF) is common in patients treated for acute heart failure (AHF) and might be associated with a significant increase in blood nitrogen urea (BUN). Although many patients develop WRF during hospitalisation, its prognostic role is still unclear. Thus, we aimed to evaluate the prognostic relevance of WRF according to BUN changes during hospitalization. We studied patients with AHF screened for Diur-HF Trial (NCT01441245). WRF was defined as an in-hospital rise in serum creatinine ≥0.3 mg/dl or estimated glomerular filtration rate (GFR) reduction ≥20%. BUN increase was defined as a rise in BUN ≥20% during admission. Effective decongestion was defined as complete resolution of two, or more, signs of HF, or absence of clinical signs of congestion at discharge. Of 247 patients enrolled, 59 (23%) patients experienced WRF, 107 (43%) had a BUN increase ≥20%, and 111 (45%) were effectively decongested during hospitalization. During 180 days of follow-up, 136 patients died or were re-hospitalised for AHF. An increase in BUN was an independent predictor of adverse outcome, regardless of WRF (HR = 2.19 [1.35-3.54], p = 0.002 and 1.71 [1.14-2.59], p = 0.010; with and without WRF, respectively) or congestion at discharge. WRF was not an independent predictor of outcome if BUN did not increase or when congestion was effectively relieved. an increase in BUN≥20% during hospitalization for AHF predicts a poor outcome independently from renal function deterioration and decongestion. WRF predicts adverse outcome only if BUN increases substantially or clinical congestion persists.

Identifiants

pubmed: 30503187
pii: S0167-5273(18)33148-6
doi: 10.1016/j.ijcard.2018.11.108
pii:
doi:

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

198-203

Informations de copyright

Copyright © 2018. Published by Elsevier B.V.

Auteurs

Alberto Palazzuoli (A)

Department of Internal Medicine, Cardiovascular Diseases Unit, University of Siena, Siena, Italy. Electronic address: palazzuoli2@unisi.it.

Gaetano Ruocco (G)

Department of Internal Medicine, Cardiovascular Diseases Unit, University of Siena, Siena, Italy.

Pierpaolo Pellicori (P)

Robertson Institute of Biostatistics and Clinical Trials Unit, University of Glasgow, University Avenue, Glasgow, G12 8QQ, United Kingdom of Great Britain and Northern Ireland.

Eufemia Incampo (E)

Cardiothoracic Department, Le Scotte Hospital, Siena, Italy.

Cristina Di Tommaso (C)

Cardiothoracic Department, Le Scotte Hospital, Siena, Italy.

Roberto Favilli (R)

Cardiothoracic Department, Le Scotte Hospital, Siena, Italy.

Isabella Evangelista (I)

Department of Internal Medicine, Cardiovascular Diseases Unit, University of Siena, Siena, Italy.

Ranuccio Nuti (R)

Department of Internal Medicine, Cardiovascular Diseases Unit, University of Siena, Siena, Italy.

Jeffrey M Testani (JM)

Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH